CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
Active, not recruiting · NCT06699836 · Registry updated 2026-09-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 2 | 2026-09-09 | NCT06699836 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CytoDyn, Inc. | 1 |
| Syneos Health | 17 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine | United States | 21 |
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Georgetown University Medical Center | Washington D.C. | United States | 62 |
| Norton Cancer Institute, Brownsboro Hospital Campus | Louisville | United States | 6 |
| Pacific Hematology Oncology Associates | San Francisco | United States | 3 |
| Summit Cancer Center | Spokane | United States | 3 |
| University of Nebraska Medical Center | Omaha | United States | 397 |